Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3
Annals of Clinical and Translational Neurology · 2026-07 · 13 (7) · 1452-1466
DOI: 10.1002/acn3.70325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 10.02.2026. Verfasst von Thiago J R Rezende und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, School of Medical Sciences, University of Campinas, Campinas, Brazil. Hauptthemen laut MEDLINE: Spinocerebellar Ataxias, Magnetic Resonance Imaging, Machado-Joseph Disease, Outcome Assessment, Health Care. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIBIB NIH HHS, Biogen, NIH HHS.
Abstract (Originalsprache)
Objective
To examine the value of MRI outcomes as endpoints for preventive and early‐stage trials of two polyglutamine spinocerebellar ataxias (SCAs).
Methods
A cohort of 100 participants (23 SCA1, 63 SCA3, median Scale for the Assessment and Rating of Ataxia (SARA) score = 5, 42% preataxic, and 14 gene‐negative controls) was scanned at 3T up to 6 times (median follow‐up 3 years) in the READISCA study. Structural, microstructural, and neurochemical outcomes were assessed for sensitivity to change. Associations between change in MR and clinical and patient‐reported outcomes were evaluated. Sample sizes were estimated for preventive trials (at preataxic stage) and early‐stage trials using the most sensitive outcomes.
Results
Infratentorial volumes, middle cerebellar peduncle (MCP) diffusivities and select neurochemical outcomes were more sensitive to change than SARA in both SCAs with moderate‐to‐high effect sizes (Cohen's d ≥ 0.5). The pons volume was the most sensitive outcome at both preataxic ( d = 1.09) and ataxic ( d = 1.48) stages. The most sensitive MR measures overlapped between genotypes, except that SCA1 showed faster progression in the cerebellum and SCA3 in the pons. Changes in MCP diffusivities and pontine neurochemical measures were associated with changes in SARA and FARS‐ADL (| r | = 0.28–0.47).
Interpretation
The estimated sample sizes to detect a 50% reduction in progression with 80% power using the pons volume as primary outcome measure indicate the feasibility of preventive trials ( n = 73 per arm in a 1‐year trial) in common SCAs and predict a 6‐fold reduction in required sample sizes relative to SARA in early interventional trials. These findings support the use of MRI endpoints in early‐stage SCA trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, School of Medical Sciences, University of Campinas, Campinas, Brazil.
- Inserm, INRIA, CNRS, APHP, Paris Brain Institute, Sorbonne Université, Paris, France.
- Department of Radiology, Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, Minnesota, USA.
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
- Department of Radiology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
- Biogen, Cambridge, Massachusetts, USA.
ORCID-Profile: Thiago J R Rezende, Sophie Tezenas du Montcel, James M Joers, Sub H Subramony, Gülin Öz
Förderung
- NIBIB NIH HHS
- Biogen
- NIH HHS
- ODCDC CDC HHS
- NCATS NIH HHS
- NINDS NIH HHS
- National Science Foundation
- University of Minnesota
Zitieren
APA
Rezende, T. J. R., Petit, E., Park, Y. W., du Montcel, S. T., Joers, J. M., DuBois, J. M., Arnold, H. M., Povazan, M., Özdemir, I., Banan, G., Valabregue, R., Ehses, P., Faber, J., Onyike, C. U., Barker, P. B., Schmahmann, J. D., Ratai, E. M., Subramony, S. H., Mareci, T. H., …, & READISCA Investigators (2026). Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3. Annals of Clinical and Translational Neurology, 13(7), 1452-1466. https://doi.org/10.1002/acn3.70325
Vancouver
Rezende TJR, Petit E, Park YW, du Montcel ST, Joers JM, DuBois JM, et al. Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3. Annals of Clinical and Translational Neurology. 2026;13(7):1452-1466. doi:10.1002/acn3.70325
BibTeX
@article{Rezende2026,
author = {Rezende, Thiago J R and Petit, Emilien and Park, Young Woo and du Montcel, Sophie Tezenas and Joers, James M and DuBois, Jonathan M and Arnold, H Moore and Povazan, Michal and Özdemir, Ipek and Banan, Guita and Valabregue, Romain and Ehses, Philipp and Faber, Jennifer and Onyike, Chiadi U and Barker, Peter B and Schmahmann, Jeremy D and Ratai, Eva-Maria and Subramony, Sub H and Mareci, Thomas H and Bushara, Khalaf O and Paulson, Henry and Klockgether, Thomas and Durr, Alexandra and Ashizawa, Tetsuo and Lenglet, Christophe and Öz, Gülin and READISCA Investigators, READISCA Investigators},
title = {Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3},
journal = {Annals of Clinical and Translational Neurology},
year = {2026},
volume = {13},
number = {7},
pages = {1452--1466},
doi = {10.1002/acn3.70325}
}
EUVIMED